Latest & greatest articles for sepsis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on sepsis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on sepsis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for sepsis

321. Statin use and hospitalization for sepsis in patients with chronic kidney disease. Full Text available with Trip Pro

Statin use and hospitalization for sepsis in patients with chronic kidney disease. Patients with chronic kidney disease are at high risk for sepsis and sepsis-related mortality.To assess whether statin use is associated with a reduction in sepsis events [corrected] in dialysis patients.National prospective cohort study that enrolled 1041 incident dialysis patients at 81 US not-for-profit outpatient dialysis clinics from October 1995 to June 1998, with follow-up to January 2005. Statin use (...) was determined by medical record review. Rates of sepsis events [corrected] between statin users and control patients were compared using multivariate regression models, with adjustment for potential confounders in the overall cohort and in a subcohort in which control patients were matched to statin users according to their likelihood (propensity) to have been prescribed a statin.Sepsis events [corrected] were determined through hospital records from the United States Renal Data System (mean follow-up, 3.4

2007 JAMA

322. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. (Abstract)

Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. Drotrecogin alfa (activated) (DrotAA) is used for the treatment of adults with severe sepsis who have a high risk of dying. A phase 1b open-label study has indicated that the pharmacokinetics and pharmacodynamics of DrotAA are similar in children and adults. We initiated the RESOLVE (REsearching severe Sepsis and Organ dysfunction in children: a gLobal perspectiVE) trial (...) to investigate the efficacy and safety of the drug in children.Children aged between 38 weeks' corrected gestational age and 17 years with sepsis-induced cardiovascular and respiratory failure were randomly assigned to receive placebo or DrotAA (24 microg/kg/h) for 96 h. We used a prospectively defined, novel primary endpoint of Composite Time to Complete Organ Failure Resolution (CTCOFR) score. Secondary endpoints were 28-day mortality, major amputations, and safety. Analysis was by intention-to-treat

2007 Lancet Controlled trial quality: predicted high

323. Meta-analysis: intravenous immunoglobulin in critically ill adult patients with sepsis

Meta-analysis: intravenous immunoglobulin in critically ill adult patients with sepsis Meta-analysis: intravenous immunoglobulin in critically ill adult patients with sepsis Meta-analysis: intravenous immunoglobulin in critically ill adult patients with sepsis Turgeon A F, Hutton B, Fergusson D A, McIntyre L, Tinmouth A A, Cameron D W, Hebert P C CRD summary This review concluded that intravenous immunoglobulin therapy improves survival compared with placebo or no treatment. Overall the authors (...) ' conclusions appear reliable. However, the included studies had some methodological limitations and the effect was primarily found in patients with severe sepsis or septic shock. Authors' objectives To evaluate the effect of polyclonal intravenous immunoglobulin (IVIG) therapy on mortality in critically ill patients with sepsis. Searching MEDLINE and the Cochrane CENTRAL Register were searched to May 2006 without any language restrictions; the search terms were reported. The bibliographies of identified

2007 DARE.

324. Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review

Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review Cruz D N, Perazella M A, Bellomo R, de Cal M, Polanco N, Corradi V, Lentini P, Nalesso F, Ueno T, Ranieri V M, Ronco C CRD summary The authors described the effect of direct haemoperfusion with polymixin B-immobilized fiber column (PMX-F (...) ) on clinical outcomes in patients with sepsis. The authors concluded that treatment appeared to have beneficial effects on blood pressure, use of vasoactive drugs, oxygenation and mortality. Limitations of the included studies and the review methodology mean that the results may not be reliable. Authors' objectives To describe the effect of direct haemoperfusion with polymixin B-immobilized fiber column (PMX-F) on blood pressure, use of vasoactive drugs, oxygenation and mortality in patients with sepsis

2007 DARE.

325. Drotrecogin alfa (activated) in severe sepsis

Drotrecogin alfa (activated) in severe sepsis Drotrecogin alfa (activated) in severe sepsis Drotrecogin alfa (activated) in severe sepsis Brophy J, Costa V Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Brophy J, Costa V. Drotrecogin alfa (activated) in severe sepsis. Montreal: Technology Assessment Unit of the McGill University Health (...) Centre (MUHC). Report #29. 2007 Authors' objectives This report evaluated the efficacy, safety and cost-effectiveness of drotrecogin alfa based on the most contemporary literature. Authors' conclusions In view of the uncertain clinical benefit, the evidence of increased risk of serious bleeding, and its high acquisition costs, the TAU recommends that drotrecogin alfa should not be used routinely in adult patients with severe sepsis at the MUHC and CHUM. The totality of the evidence suggests

2007 Health Technology Assessment (HTA) Database.

326. The COASST study: cost-effectiveness of albumin in severe sepsis and septic shock

The COASST study: cost-effectiveness of albumin in severe sepsis and septic shock The COASST study: cost-effectiveness of albumin in severe sepsis and septic shock The COASST study: cost-effectiveness of albumin in severe sepsis and septic shock Guidet B, Mosqueda GJ, Priol G, Aegerter P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to estimate the cost-effectiveness of albumin-based fluid support for patients with severe sepsis or septic shock, or both. The authors concluded that albumin infusion was cost-effective for treating severe sepsis in the intensive care unit. There were issues with the reporting of the study, the methods, and the lack of sensitivity analysis; the authors' conclusions should be treated

2007 NHS Economic Evaluation Database.

327. Implementation of early goal-directed therapy for severe sepsis and septic shock: a decision analysis

Implementation of early goal-directed therapy for severe sepsis and septic shock: a decision analysis Implementation of early goal-directed therapy for severe sepsis and septic shock: a decision analysis Implementation of early goal-directed therapy for severe sepsis and septic shock: a decision analysis Huang D T, Clermont G, Dremsizov T T, Angus D C Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains (...) a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The authors aimed to evaluate the cost-effectiveness of early goal-directed therapy (EGDT) for the management of severe sepsis and septic shock. They concluded that EGDT, despite its higher implementation costs, can be cost-saving to the hospital and cost-effective over a lifetime. The quality of the study was satisfactory

2007 NHS Economic Evaluation Database.

328. Is lumbar puncture necessary for evaluation of early neonatal sepsis?

Is lumbar puncture necessary for evaluation of early neonatal sepsis? BestBets: Is lumbar puncture necessary for evaluation of early neonatal sepsis? Is lumbar puncture necessary for evaluation of early neonatal sepsis? Report By: B Ray, J Mangalore, C Harikumar and A Tuladhar - Specialist Registrars Search checked by Bob Phillips - Section Editor, Archimedes, Archives of Disease in Childhood Institution: Paediatrics, Northern Deanery, Newcastle upon Tyne and University Hospital of North Tees (...) , Stockton Date Submitted: 14th December 2006 Date Completed: 14th December 2006 Last Modified: 14th December 2006 Status: Green (complete) Three Part Question In [a newborn] is [lumbar puncture necessary] to [rule out meningitis in suspected sepsis in the first few days of life (0–3 days)]? Clinical Scenario A newborn baby born at 37 weeks is noted to be unwell at 18 h postnatally. The mother gives a history of prolonged rupture of membranes for 36 h. The baby is feeding poorly and is jittery

2007 BestBETS

329. Neutrophils in development of multiple organ failure in sepsis. (Abstract)

Neutrophils in development of multiple organ failure in sepsis. Multiple organ failure is a major threat to the survival of patients with sepsis and systemic inflammation. In the UK and in the USA, mortality rates are currently comparable with and projected to exceed those from myocardial infarction. The immune system combats microbial infections but, in severe sepsis, its untoward activity seems to contribute to organ dysfunction. In this Review we propose that an inappropriate activation (...) and positioning of neutrophils within the microvasculature contributes to the pathological manifestations of multiple organ failure. We further suggest that targeting neutrophils and their interactions with blood vessel walls could be a worthwhile therapeutic strategy for sepsis.

2006 Lancet

330. Recombinant human activated protein C for severe sepsis in neonates. (Abstract)

Recombinant human activated protein C for severe sepsis in neonates. Sepsis is a common problem in both preterm and term infants. Although the overall incidence of neonatal sepsis has declined over the past decade, mortality remains high. Recombinant human activated protein C (rhAPC) has been shown to possess a broad spectrum of activity modulating coagulation and has been shown in septic adults to reduce mortality. In septic children, an open label study has shown similar pharmacokinetics (...) or confirmed severe sepsis in term and preterm infants less than 28 days old. Eligible trials were required to report treatment effects on at least one of the following outcomes: all cause mortality during initial hospital stay, neurological development and neurodevelopmental assessment at two years of age or later, length of hospital stay, duration of ventilation, chronic lung disease in survivors, periventricular leukomalacia, intraventricular hemorrhage, necrotizing enterocolitis, bleeding, and any

2006 Cochrane

331. Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. (Abstract)

Statins and sepsis in patients with cardiovascular disease: a population-based cohort analysis. Atherosclerosis and sepsis share several pathophysiological similarities, including immune dysregulation, increased thrombogenesis, and systemic inflammation. The relation between statins and risk of sepsis in patients with atherosclerosis is unknown.We did a population-based cohort analysis through linked administrative databases in Ontario, Canada, with accrual from 1997 to 2002. We identified (...) 141,487 patients older than 65 years who had been hospitalised for an acute coronary syndrome, ischaemic stroke, or revascularisation, who survived for at least 3 months after discharge. 46,662 (33%) were prescribed a statin within 90 days of discharge, 94,825 (67%) were not. Propensity-based matching, which accounted for each individual's likelihood of receiving a statin, yielded a cohort of 69,168 patients, of whom half (34,584) received a statin and half (34,584) did not.Incidence of sepsis

2006 Lancet

332. Cost-effectiveness of a post-splenectomy registry for prevention of sepsis in the asplenic

Cost-effectiveness of a post-splenectomy registry for prevention of sepsis in the asplenic Cost-effectiveness of a post-splenectomy registry for prevention of sepsis in the asplenic Cost-effectiveness of a post-splenectomy registry for prevention of sepsis in the asplenic Woolley I, Jones P, Spelman D, Gold L Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study objective was to assess the cost-effectiveness of a post-splenectomy registry for the prevention of sepsis in asplenic patients. The authors concluded that a registry-based approach to treatment was likely to be cost-effective in terms of mortality and rates of overwhelming post-splenectomy infection. There are limitations in the study methodology which mean the authors

2006 NHS Economic Evaluation Database.

333. Intravenous polyclonal IgM-enriched immunoglobulin therapy in sepsis: a review of clinical efficacy in relation to microbiological aetiology and severity of sepsis Full Text available with Trip Pro

Intravenous polyclonal IgM-enriched immunoglobulin therapy in sepsis: a review of clinical efficacy in relation to microbiological aetiology and severity of sepsis Intravenous polyclonal IgM-enriched immunoglobulin therapy in sepsis: a review of clinical efficacy in relation to microbiological aetiology and severity of sepsis Intravenous polyclonal IgM-enriched immunoglobulin therapy in sepsis: a review of clinical efficacy in relation to microbiological aetiology and severity of sepsis Norrby (...) of patients with sepsis. Searching MEDLINE database and relevant published Cochrane reviews were searched. Search terms and dates were not reported. Study selection Controlled studies of IgM-enriched IVIG treatment in patients with sepsis were eligible for inclusion. Included studies were of IgM-enriched IVIG; dosages ranging from 200mg/100g to 500mg/100g. Control conditions in the included studies were no intervention, 10% dextran or 5% albumin. Study designs included for review were prospective

2006 DARE.

334. A systematic review of antithrombin concentrate use in patients with disseminated intravascular coagulation of severe sepsis

A systematic review of antithrombin concentrate use in patients with disseminated intravascular coagulation of severe sepsis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2006 DARE.

335. Use of methylene blue in sepsis: a systematic review

Use of methylene blue in sepsis: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2006 DARE.

336. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis with multiple organ failure

Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis with multiple organ failure Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis with multiple organ failure Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis with multiple organ failure Franca L R, Launois R, Le Lay K, Aegerter P, Bouhassira M, Meshaka P, Guidet B Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The addition of drotrecogin alpha (activated) (DAA) to best standard care (BSC) for the treatment of severe sepsis with multiple organ failure (MOF) was examined. DAA was administrated as a continuous intravenous infusion at a rate of 24 microg/kg per hour for 96 hours

2006 NHS Economic Evaluation Database.

337. Evaluation of the cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom

Evaluation of the cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom Evaluation of the cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom Evaluation of the cost-effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom Green C, Dinnes J, Takeda A L, Cuthbertson B H Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study compared two treatment options for severe sepsis. Drotrecogin alfa (activated), i.e. the recombinant form of human activated protein C, plus conventional care was compared with conventional care alone. Conventional care was not described

2006 NHS Economic Evaluation Database.

338. Drotrecogin alfa (activated) should not be used in patients with severe sepsis and low risk for death Full Text available with Trip Pro

Drotrecogin alfa (activated) should not be used in patients with severe sepsis and low risk for death Drotrecogin alfa (activated) should not be used in patients with severe sepsis and low risk for death | Critical Care | Full Text Advertisement Menu Search Search all BMC articles Search Menu Table of Contents , Eric B Milbrandt and Lakshmipathi Chelluri Critical Care 2006 10 :316 © BioMed Central Ltd 2006 Published: 03 November 2006 Citation Abraham E, Laterre PF, Garg R, Levy H, Talwar D (...) , Trzaskoma BL, Francois B, Guy JS, Bruckmann M, Rea-Neto A, Rossaint R, Perrotin D, Sablotzki A, Arkins N, Utterback BG, Macias WL: Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005, 353:1332–1341 [ ]. Background In November 2001, the Food and Drug Administration (FDA) approved drotrecogin alfa (activated) (DrotAA) for adults who had severe sepsis and a high risk of death. The FDA required a study to evaluate the efficacy of DrotAA for adults who had

2006 Critical Care - EBM Journal Club

339. Mitochondrial DNA and survival after sepsis: a prospective study. (Abstract)

Mitochondrial DNA and survival after sepsis: a prospective study. Human genome evolution has been shaped by infectious disease. Although most genetic studies have focused on the immune system, recovery after sepsis is directly related to physiological reserve that is critically dependent on mitochondrial function. We investigated whether haplogroup H, the most common type of mitochondrial DNA (mtDNA) in Europe, contributes to the subtle genetic variation in survival after sepsis.In (...) to the intensive care unit, the frequency of mtDNA haplogroup H in study patients did not differ between study patients admitted with severe sepsis and 542 age-matched controls from the northeast of England. MtDNA haplogroup H was a strong independent predictor of outcome during severe sepsis, conferring a 2.12-fold (95% CI 1.02-4.43) increased chance of survival at 180 days compared with individuals without the haplogroup H.Although haplogroup H is the most recent addition to the group of European mtDNA

2005 Lancet

340. Staphylococcus aureus sepsis and the Waterhouse-Friderichsen syndrome in children. (Abstract)

Staphylococcus aureus sepsis and the Waterhouse-Friderichsen syndrome in children. Staphylococcus aureus has increasingly been recognized as a cause of severe invasive illness. We describe three children who died at our institution after rapidly progressive clinical deterioration from this infection, with necrotizing pneumonia and multiple-organ-system involvement. The identification of bilateral adrenal hemorrhage at autopsy was characteristic of the Waterhouse-Friderichsen syndrome

2005 NEJM